← Back to Screener
Nexalin Technology, Inc. Common Stock (NXL)
Price$0.46
Favorite Metrics
Price vs S&P 500 (26W)-76.62%
Price vs S&P 500 (4W)19.67%
Market Capitalization$10.48M
All Metrics
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)10.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-38.88%
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)-11.42%
Gross Margin (TTM)79.65%
Net Profit Margin (TTM)-2725.65%
EPS (TTM)$-0.51
10-Day Avg Trading Volume1.93M
EPS Excl Extra (TTM)$-0.51
Revenue Growth (5Y)4.43%
EPS (Annual)$-0.50
ROI (Annual)-206.94%
Gross Margin (Annual)79.66%
Net Profit Margin (5Y Avg)-3155.40%
Cash / Share (Quarterly)$0.19
Revenue Growth QoQ (YoY)531.99%
ROA (Last FY)-180.15%
Revenue Growth TTM (YoY)78.81%
EBITD / Share (TTM)$-0.51
Operating Margin (TTM)-2781.57%
Cash Flow / Share (Annual)$-0.30
P/B Ratio2.80x
P/B Ratio (Quarterly)2.78x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)32.56x
Net Interest Coverage (TTM)-27.58x
ROA (TTM)-171.07%
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)7.25x
Quick Ratio (Quarterly)4.29x
3-Month Avg Trading Volume0.47M
52-Week Price Return-71.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.18
P/S Ratio (Annual)34.73x
Asset Turnover (Annual)0.04x
52-Week High$2.31
Operating Margin (5Y Avg)-3252.44%
EPS Excl Extra (Annual)$-0.50
CapEx CAGR (5Y)121.02%
26-Week Price Return-72.63%
Quick Ratio (Annual)6.39x
13-Week Price Return-28.32%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.85x
Enterprise Value$9.821
Revenue / Share Growth (5Y)-11.24%
Asset Turnover (TTM)0.06x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.22x
Pretax Margin (Annual)-2725.74%
Cash / Share (Annual)$0.26
3-Month Return Std Dev96.88%
Gross Margin (5Y Avg)78.47%
Net Income / Employee (TTM)$-1
ROE (Last FY)-206.94%
Net Interest Coverage (Annual)-27.97x
EPS Basic Excl Extra (Annual)$-0.50
Receivables Turnover (TTM)6.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.51
Receivables Turnover (Annual)15.06x
ROI (TTM)-195.71%
P/S Ratio (TTM)34.73x
Pretax Margin (5Y Avg)-3155.40%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.26
Price vs S&P 500 (52W)-101.23%
Year-to-Date Return-8.78%
5-Day Price Return33.95%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-801.91%
Net Profit Margin (Annual)-2725.74%
Month-to-Date Return46.14%
Cash Flow / Share (TTM)$-0.63
EBITD / Share (Annual)$-0.51
Operating Margin (Annual)-2781.66%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.51
P/TBV (Quarterly)3.05x
P/B Ratio (Annual)9.66x
Inventory Turnover (TTM)0.40x
Pretax Margin (TTM)-2725.65%
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)-29.01%
Beta4.33x
Revenue / Share (TTM)$0.02
ROE (TTM)-195.71%
52-Week Low$0.33
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NXLNexalin Technology, Inc. Common Stock | 34.73x | 4.43% | 79.65% | -2781.57% | $0.46 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.65 |
MASIMasimo Corporation | 6.12x | 5.95% | 61.90% | 20.30% | $178.29 |
TMDXTransMedics Group, Inc. Common Stock | 6.58x | 88.21% | 59.92% | 17.93% | $109.12 |
LIVNLivaNova PLC Ordinary Shares | 2.56x | 8.24% | 68.04% | 14.09% | $65.01 |
ITGRInteger Holdings Corporation | 1.63x | 11.55% | 27.39% | 11.90% | $88.37 |
AXGNAxogen, Inc. Common Stock | 7.92x | 14.93% | 74.31% | -3.49% | $37.37 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $37.91 |
BLFSBioLife Solutions Inc. | 10.59x | 14.87% | 64.56% | -17.26% | $20.85 |
INMDInMode Ltd. Ordinary Shares | 2.45x | 12.45% | 78.54% | 23.05% | $14.33 |
CBLLCeriBell, Inc. Common Stock | 8.68x | — | 87.89% | -65.57% | $20.74 |
About
Nexalin Technology develops bioelectronic neurostimulation devices for treating anxiety and insomnia without medications or psychotherapy. The company's Generation 1 product is a cranial electrotherapy stimulation (CES) device that delivers targeted neural stimulation. As a Class II FDA-cleared device, it represents a non-pharmacological treatment option in the mental health care market.